Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2325-2334

  Jacobsen, F ^a   Fisahn, C ^a   Sorkin, M ^a   Thiele, I ^a   Hirsch, T ^a   Stricker, I ^a   Klaassen, T ^b   Roemer, A ^b   Fugmann, B ^c   Steinstraesser, L ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Institute of Analytic and Metabolic Science   (Germany)

^c Bayer Innovation GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; LINEZOLID; MOXIFLOXACIN; PSEUDOMONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BLOOD SAMPLING; BURN INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL PIG; EXPERIMENTAL RAT; FEMALE; FOLLOW UP; GEL; HISTOLOGY; INOCULATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RAT; TOPICAL TREATMENT; WOUND FLUID; WOUND HEALING; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANIMALS; AZA COMPOUNDS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; QUINOLINES; RATS; SWINE; WOUND INFECTION;

EID: 79955527627     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01071-10     Document Type: Article

References (30)

1. Boucher, H. W., and G. R. Corey. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S344-S349.
2. Choi, J. H., et al. 2003. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 47:3704-3707.
3. CLSI. 2006. Performance standards for antimicrobial disk susceptibility tests, 9th ed. Approved standard M2-A9. CLSI, Wayne, PA.
4. Dalhoff, A. 2005. Immunomodulatory activities of fluoroquinolones. Infection 33(Suppl. 2):55-70.
5. Desrosiers, M., Z. Bendouah, and J. Barbeau. 2007. Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am. J. Rhinol. 21:149-153.
6. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
7. Fawley, W. N., P. Parnell, J. Hall, and M. H. Wilcox. 2006. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J. Hosp. Infect. 62:327-332.
8. Franz, M. G., et al. 2008. Guidelines to aid healing of acute wounds by decreasing impediments of healing. Wound Repair Regen. 16:723-748.
9. Garau, J., E. Bouza, J. Chastre, F. Gudiol, and S. Harbarth. 2009. Management of methicillin-resistant Staphylococcus aureus infections. Clin. Microbiol. Infect. 15:125-136.
10. Giordano, P., J. Song, P. Pertel, J. Herrington, and S. Kowalsky. 2005. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin- tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int. J. Antimicrob. Agents 26:357-365.
11. Guay, D. R. 2006. Moxifloxacin in the treatment of skin and skin structure infections. Ther. Clin. Risk Manag. 2:417-434.
12. Hirsch, T., et al. 2008. Enhanced susceptibility to infections in a diabetic wound healing model. BMC Surg. 8:5.
13. Jacobsen, F., et al. 2005. Activity of histone H1.2 in infected burn wounds. J. Antimicrob. Chemother. 55:735-741.
14. Jacobsen, F., et al. 2005. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther. 12:1494-1502. (Pubitemid 41508674)
15. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
16. Lentino, J. R., M. Narita, and V. L. Yu. 2008. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27:3-15.
17. McConeghy, K. W., D. J. Mikolich, and K. L. LaPlante. 2009. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 29:263-280.
18. Neely, A. N., et al. 2009. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J. Burn Care Res. 30:19-29.
19. Norrby, S. R., C. E. Nord, and R. Finch. 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5:115-119.
20. O'Meara, S., et al. 2006. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet. Med. 23:341-347.
21. Parish, L. C., et al. 2000. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54:497-503.
22. Robson, M. C., R. J. Mannari, P. D. Smith, and W. G. Payne. 1999. Maintenance of wound bacterial balance. Am. J. Surg. 178:399-402.
23. Steinstraesser, L., et al. 2002. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob. Agents Chemother. 46:1837-1844.
24. Steinstraesser, L., et al. 2006. A novel titanium wound chamber for the study of wound infections in pigs. Comp. Med. 56:279-285.
25. Stryjewski, M. E., and G. R. Corey. 2009. New treatments for methicillin-resistant Staphylococcus aureus. Curr. Opin. Crit. Care 15:403-412.
26. Tammelin, A., C. Lindholm, and A. Hambraeus. 1998. Chronic ulcers and antibiotic treatment. J. Wound Care 7:435-437.
27. Tuberculosis. 2008. Moxifloxacin. Tuberculosis 88:127-131.
28. Vardaxis, N. J., T. A. Brans, M. E. Boon, R. W. Kreis, and L. M. Marres. 1997. Confocal laser scanning microscopy of porcine skin: implications for human wound healing studies. J. Anat. 190(4):601-611.
29. Wang, J. F., M. E. Olson, C. R. Reno, J. B. Wright, and D. A. Hart. 2001. The pig as a model for excisional skin wound healing: characterization of the molecular and cellular biology, and bacteriology of the healing process. Comp. Med. 51:341-348.
30. Weiss, T., et al. 2004. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother. 48:1974-1982.